ADAM33 Gene Polymorphisms and Mortality. A Prospective Cohort Study

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Figarska, Sylwia M ^a   Vonk, Judith M ^a   van Diemen, Cleo C ^a   Postma, Dirkje S ^a   Boezen, H Marike ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM33 PROTEIN; UNCLASSIFIED DRUG;

ADAM33 GENE; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY HEIGHT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENDER; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLEIOTROPY; RESIDENTIAL AREA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; WILD TYPE;

ADAM PROTEINS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 84879820524     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067768     Document Type: Article

References (24)

1. Blagosklonny MV, (2010) Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging" hypothesis. Aging (Albany NY) 2: 177-182.
2. Swindell WR, Ensrud KE, Cawthon PM, Cauley JA, Cummings SR, et al. (2010) Indicators of "Healthy Aging" in older women (65-69 years of age). A data-mining approach based on prediction of long-term survival. BMC Geriatr 10: 55.
3. Lao JI, Montoriol C, Morer I, Beyer K, (2005) Genetic contribution to aging: deleterious and helpful genes define life expectancy. Ann N Y Acad Sci 1057: 50-63.
4. Seals DF, Courtneidge SA, (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17: 7-30.
5. Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, et al. (2002) Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418: 426-430.
6. Holloway JW, Laxton RC, Rose-Zerilli MJ, Holloway JA, Andrews AL, et al. (2010) ADAM33 expression in atherosclerotic lesions and relationship of ADAM33 gene variation with atherosclerosis. Atherosclerosis 211: 224-30.
7. Edwards DR, Handsley MM, Pennington CJ, (2008) The ADAM metalloproteinases. Mol Aspects Med 29: 258-289.
8. Butcher SK, Lord JM, (2004) Stress responses and innate immunity: aging as a contributory factor. Aging Cell 3: 151-160.
9. Naumova E, Mihaylova A, Ivanova M, Michailova S, Penkova K, et al. (2004) Immunological markers contributing to successful aging in Bulgarians. Exp Gerontol 39: 637-644.
10. Gosman MM, Boezen HM, van Diemen CC, Snoeck-Stroband JB, Lapperre TS, et al. (2007) A disintegrin and metalloprotease 33 and chronic obstructive pulmonary disease pathophysiology. Thorax 62: 242-247.
11. van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP, et al. (2005) A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med 172: 329-333.
12. Blakey JD, Sayers I, Ring SM, Strachan DP, Hall IP, (2009) Positionally cloned asthma susceptibility gene polymorphisms and disease risk in the British 1958 Birth Cohort. Thorax 64: 381-387.
13. Tripathi P, Awasthi S, Prasad R, Ganesh S, (2012) Haplotypic association of ADAM33 (T+1, S+1 and V- 3) gene variants in genetic susceptibility to asthma in Indian population. Ann Hum Biol 39: 479-83.
14. Korytina GF, Tselousova OS, Akhmadishina LZ, Victorova EV, Zagidullin S, et al. (2012) Association of the MMP3, MMP9, ADAM33 and TIMP3 genes polymorphic markers with development and progression of chronic obstructive pulmonary disease. Mol Biol (Mosk) 46: 487-499.
15. Lee YH, Song GG, (2012) Association between ADAM33 T1 polymorphism and susceptibility to asthma in Asians. Inflamm Res 61: 1355-1362.
16. Holgate ST, (2010) ADAM metallopeptidase domain 33 (ADAM33): identification and role in airways disease. Drug News Perspect 23: 381-387.
17. Sadeghnejad A, Ohar JA, Zheng SL, Sterling DA, Hawkins GA, et al. (2009) Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers. Respir Res 10: 21.
18. Chen C, Huang X, Sheppard D, (2006) ADAM33 is not essential for growth and development and does not modulate allergic asthma in mice. Mol Cell Biol 26: 6950-6956.
19. Haitchi HM, Powell RM, Shaw TJ, Howarth PH, Wilson SJ, et al. (2005) ADAM33 expression in asthmatic airways and human embryonic lungs. Am J Respir Crit Care Med 171: 958-965.
20. Simpson A, Maniatis N, Jury F, Cakebread JA, Lowe LA, et al. (2005) Polymorphisms in a disintegrin and metalloprotease 33 (ADAM33) predict impaired early-life lung function. Am J Respir Crit Care Med 172: 55-60.
21. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, et al. (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8: 35-40.
22. Puxeddu I, Pang YY, Harvey A, Haitchi HM, Nicholas B, et al. (2008) The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol 121: 1400-1406.
23. Streiner DL, Norman GR, (2011) Correction for multiple testing: is there a resolution? Chest 140: 16-18.
24. Rothman KJ, (1990) No adjustments are needed for multiple comparisons. Epidemiology 1: 43-46.